Literature DB >> 9051700

Losartan influences behavioural effects of angiotensin II in rats.

A Kułakowska1, W Karwowska, K Wiśniewski, J J Braszko.   

Abstract

The role of the angiotensin AT1 receptors in certain behavioural effects of angiotensin II (Ang II), using their selective antagonist losartan (DuP 753), was assessed. Ang II, given intracerebroventricularly (ICV) at the dose of 1 nmole, significantly improved object recognition, learning of conditioned avoidance responses (CARs), and recall of a passive avoidance behaviour. Losartan alone (1 microgram) was ineffective in any test except for the elevated 'plus' maze measuring anxiety which was diminished by the drug, both in peptide treated and in control rats. Losartan, given 5 min before Ang II, abolished improved after the peptide recall of the passive avoidance and object recognition. Losartan did not influence increased after Ang II rate of CARs acquisition. None of the treatments significantly changed behaviour of rats in the open field. The results point to the considerable involvement of the AT1 angiotensin receptors in the cognition improving effects of Ang II. However, unspecific psychoactivity of losartan should also be taken into account.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9051700     DOI: 10.1006/phrs.1996.0073

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  10 in total

1.  Cognitive enhancement following acute losartan in normotensive young adults.

Authors:  Rasha Mechaeil; Paul Gard; Anne Jackson; Jennifer Rusted
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

2.  Angiotensin II AT1 receptor blockade ameliorates brain inflammation.

Authors:  Julius Benicky; Enrique Sánchez-Lemus; Masaru Honda; Tao Pang; Martina Orecna; Juan Wang; Yan Leng; De-Maw Chuang; Juan M Saavedra
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

Review 3.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

4.  Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice.

Authors:  Björn Maul; Oliver von Bohlen und Halbach; Axel Becker; Anja Sterner-Kock; Jörg-Peter Voigt; Wolf-Eberhard Siems; Gisela Grecksch; Thomas Walther
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

5.  Effects of Goldblatt hypertension on rats' hippocampal cholinergic system.

Authors:  Hamid Sepehri; Farzaneh Ganji; Zahra Nazari; Marzieh Vahid
Journal:  Transl Neurosci       Date:  2022-04-20       Impact factor: 1.264

6.  Angiotensin type 1 receptor inhibition enhances the extinction of fear memory.

Authors:  Paul J Marvar; Jared Goodman; Sebastien Fuchs; Dennis C Choi; Sunayana Banerjee; Kerry J Ressler
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

7.  Roles of Brain Angiotensin II in Cognitive Function and Dementia.

Authors:  Masaki Mogi; Jun Iwanami; Masatsugu Horiuchi
Journal:  Int J Hypertens       Date:  2012-12-11       Impact factor: 2.420

8.  Fear-potentiated behaviour is modulated by central amygdala angiotensin II AT1 receptors stimulation.

Authors:  Maria de los Angeles Marinzalda; Pablo A Pérez; Pascual A Gargiulo; Brenda S Casarsa; Claudia Bregonzio; Gustavo Baiardi
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

Review 9.  Could Management of Blood Pressure Prevent Dementia in the elderly?

Authors:  Masaki Mogi
Journal:  Clin Hypertens       Date:  2019-12-10

Review 10.  Brain Renin-Angiotensin System at the Intersect of Physical and Cognitive Frailty.

Authors:  Caglar Cosarderelioglu; Lolita S Nidadavolu; Claudene J George; Esther S Oh; David A Bennett; Jeremy D Walston; Peter M Abadir
Journal:  Front Neurosci       Date:  2020-09-30       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.